- Email: [email protected]
Flowering genes
l
> !%quence d’ADN codant pour une cynnamoyl-CoA rbductase, et leurs applications dans le domaine de la regulation des teneurs en lignines des plantes (A Boudet et al, FR)
CNRS, lnra N” 2739395, FR. > Cytoplasmic male sterile Bras&a oleracea plants which contain the polima CMS cytoplasm and are male sterile at high and low temperatures (A Elsenga-Boersma et F van den Bosch, NL)
Petoseed Company Inc and the inventors N” WO 97109873. PCT. > Flowering Bradley et
genes
(D
a/, UK)
John lnnes Centre and the inventors N” WO 97110339, PCT. The ten gene of Antirrhinum has been cloned, also homologues from Arabidopsis (tfll) and rice. Flowering characteristics of transgenic plants, especially switching of apical meristem to a floral fate and the timing of flowering, may be manipulated by regulating gene expression...
> Utilisation d’antagonistes de la bradykinine pour stimuler ou induite la pousse de cheveux etfou stopper leur chute (F Pruche et al, FR)
les derniers brevets deposks rkalis6e en collaboration
cleic acid sequences encoding medically useful proteins, pharmaceutical formulations, and methods for expressing the proteins. In particular, higher primate leptin protein cDNA sequences are disclosed as are the expressed proteins. > Transcriptional co-repressor that interacts with nuclear hormone receptors and uses iherefor (RM Evans et J Chen, US)
The Salk Institute for Biological Studies N” WO 97/09418, PCT. ... there are provided novel receptor interacting factors, referred to herein as SMRT, ie a Silencing Mediator (corepressor) for Retionic Acid Receptor (RAR) and Thyroid hormone Receptor (TR). The interaction of SMRT with mutant receptors correlates with the transcriptional silencing activities of receptors. In viz/o, SMRT functions as a potent co-repressor. A GALCDNA binding domain (DBD) fusion of SMRT behaves as a frank repressor of a GAL4dependent reporter...
> Nouvelles membranaires
bacterpylori
protbines d’He/ico(L Kang, FR)
Pasteur Mbrieux S&urns et Vaccins N” 2739622 ET 2739623, FR. L’invention a pour objet une prottine d’Helicobacter pyiori sous forme substantiellement purifike, susceptible d’&re obtenue h partir d’une fraction membranaire d’H pylori et dont le poids moEculaire aprts Plectrophor&e sur gel de polyacrylamide 10 % en prCsence de SDS apparait de l’ordre de 76,54,50 ou 30 kDa.
L’Orkal N” 2739553, FR.
> Acellular vaccine (IG Charles et NF Fairweather, UK)
> DNA encoding primate leptins as medicinal proteins (MB Basinski et al,
Medeva Holdings BV N” 764445, EP. A vaccine suitable for use in inducing immunity to whooping cough in humans comprises a synergistic combination of the 69 kDa antigen
US)
Eli Lilly and Company N” 764722, EP. The invention includes nu82 BIOFUTUR168 l Juin 1997
: morceaux choisis avec I’lnpi
of Bordetella pertussis and toxoided IymphocyTosis promoting factor of B pertussis. > Bacterial delivery (A Branstrom et
system
l
pression or activity; IGFBP3 itself; or an expression vector comprising a nucleotide sequence encoding IGFBP3...
al, US)
Department of the Army, US Government and the inventors N” WO 97/08955, PCT. This invention relates to a method of introducing functional nucleic acids into cells using a bacterial delivery system. The delivery system can be used as a vaccme to prevent or treat infectious diseases. This invention can be applied to any desired bacteria including attenuated strains of Shigelh.
> Treatment of diabetes via administration of hormonally ineffective insulin (v Wang, US)
Alexion Pharmaceuticals Inc N” WO 97/09061, PCT. Novel immunomodulatory methods for both the prevention and treatment of type I diabetes mellitus are provided. These methods comprise the administration of doses containing measured amounts (preferably superphysiologic amounts) of an adjuvant free hormonally ineffective insulin related polypeptide to the patient. Preferably this administration is carried out on a schedule designed to induce apoptosis, anergy or other modulation of the autoimmune activity of T cells reactive with at least one epitope of the hormonally ineffective insulin related polypeptide. r;er > Insulin-like growth factor binding protein 3 (IGFBP3) in treatment of p53related tumors (L Buckbinder et a/, US)
Bristol-Myers Squibb Company N” WO 97/09998, PCT. Methods of treating p53-related tumors by administering a modulator of IGFBP3, wherein the modulator upregulates IGF-BP3 ex-
> Cloning gens (WR
of mite Thomas
aller-
et al,
AU)
Institute for Child Health Research N” 765936. EP. Recombinant DNA expression vectors or cloning vehicles capable of expressing a polypeptide displaying the antigenicity of an allergen of house dust mites of the genus Dermatophagoides. ,A synthetic protein or polypeptide displaying the antigenicity of all or a portion of an allergen of house dust mites of the genus Devrmtophagoides. Methods of diagnosis and treating such allergies. > Diagnosis and treatment of neurological disease (GA Rosenberg et a/, US)
University of New Mexico, the Government of the United States of America, the Department of Health and Human Services N” WO 97109038, PCT. The invention provides a method for the diagnosis and treatment of neurological diseases or disorders characterized by disruption of the blood/brain barrier. The 92 kDa zymogen of gelatinase B and active gelatinase B are markers of neuropathologies associated with disruption of the blood/brain barrier.
> Utilisation d’un vecteur assurant I’expression ou I’augmentation transitoire de I’activit6 Bcl-2 (A Kahn et al, FR)
lnserm N” 2739561, FR. ... dans un ou plusieurs organes, pour la rkalisation d’un mtdicament destinC au traitement ou la prevention d’une defaillance aiguE d’un ou plusieurs organes impliquant un processus apoptotique, par inhibition totale ou partielle du signal apoptotique.
> !%quence d’ADN codant pour une cynnamoyl-CoA rbductase, et leurs applications dans le domaine de la regulation des teneurs en lignines des plantes (A Boudet et al, FR)
CNRS, lnra N” 2739395, FR. > Cytoplasmic male sterile Bras&a oleracea plants which contain the polima CMS cytoplasm and are male sterile at high and low temperatures (A Elsenga-Boersma et F van den Bosch, NL)
Petoseed Company Inc and the inventors N” WO 97109873. PCT. > Flowering Bradley et
genes
(D
a/, UK)
John lnnes Centre and the inventors N” WO 97110339, PCT. The ten gene of Antirrhinum has been cloned, also homologues from Arabidopsis (tfll) and rice. Flowering characteristics of transgenic plants, especially switching of apical meristem to a floral fate and the timing of flowering, may be manipulated by regulating gene expression...
> Utilisation d’antagonistes de la bradykinine pour stimuler ou induite la pousse de cheveux etfou stopper leur chute (F Pruche et al, FR)
les derniers brevets deposks rkalis6e en collaboration
cleic acid sequences encoding medically useful proteins, pharmaceutical formulations, and methods for expressing the proteins. In particular, higher primate leptin protein cDNA sequences are disclosed as are the expressed proteins. > Transcriptional co-repressor that interacts with nuclear hormone receptors and uses iherefor (RM Evans et J Chen, US)
The Salk Institute for Biological Studies N” WO 97/09418, PCT. ... there are provided novel receptor interacting factors, referred to herein as SMRT, ie a Silencing Mediator (corepressor) for Retionic Acid Receptor (RAR) and Thyroid hormone Receptor (TR). The interaction of SMRT with mutant receptors correlates with the transcriptional silencing activities of receptors. In viz/o, SMRT functions as a potent co-repressor. A GALCDNA binding domain (DBD) fusion of SMRT behaves as a frank repressor of a GAL4dependent reporter...
> Nouvelles membranaires
bacterpylori
protbines d’He/ico(L Kang, FR)
Pasteur Mbrieux S&urns et Vaccins N” 2739622 ET 2739623, FR. L’invention a pour objet une prottine d’Helicobacter pyiori sous forme substantiellement purifike, susceptible d’&re obtenue h partir d’une fraction membranaire d’H pylori et dont le poids moEculaire aprts Plectrophor&e sur gel de polyacrylamide 10 % en prCsence de SDS apparait de l’ordre de 76,54,50 ou 30 kDa.
L’Orkal N” 2739553, FR.
> Acellular vaccine (IG Charles et NF Fairweather, UK)
> DNA encoding primate leptins as medicinal proteins (MB Basinski et al,
Medeva Holdings BV N” 764445, EP. A vaccine suitable for use in inducing immunity to whooping cough in humans comprises a synergistic combination of the 69 kDa antigen
US)
Eli Lilly and Company N” 764722, EP. The invention includes nu82 BIOFUTUR168 l Juin 1997
: morceaux choisis avec I’lnpi
of Bordetella pertussis and toxoided IymphocyTosis promoting factor of B pertussis. > Bacterial delivery (A Branstrom et
system
l
pression or activity; IGFBP3 itself; or an expression vector comprising a nucleotide sequence encoding IGFBP3...
al, US)
Department of the Army, US Government and the inventors N” WO 97/08955, PCT. This invention relates to a method of introducing functional nucleic acids into cells using a bacterial delivery system. The delivery system can be used as a vaccme to prevent or treat infectious diseases. This invention can be applied to any desired bacteria including attenuated strains of Shigelh.
> Treatment of diabetes via administration of hormonally ineffective insulin (v Wang, US)
Alexion Pharmaceuticals Inc N” WO 97/09061, PCT. Novel immunomodulatory methods for both the prevention and treatment of type I diabetes mellitus are provided. These methods comprise the administration of doses containing measured amounts (preferably superphysiologic amounts) of an adjuvant free hormonally ineffective insulin related polypeptide to the patient. Preferably this administration is carried out on a schedule designed to induce apoptosis, anergy or other modulation of the autoimmune activity of T cells reactive with at least one epitope of the hormonally ineffective insulin related polypeptide. r;er > Insulin-like growth factor binding protein 3 (IGFBP3) in treatment of p53related tumors (L Buckbinder et a/, US)
Bristol-Myers Squibb Company N” WO 97/09998, PCT. Methods of treating p53-related tumors by administering a modulator of IGFBP3, wherein the modulator upregulates IGF-BP3 ex-
> Cloning gens (WR
of mite Thomas
aller-
et al,
AU)
Institute for Child Health Research N” 765936. EP. Recombinant DNA expression vectors or cloning vehicles capable of expressing a polypeptide displaying the antigenicity of an allergen of house dust mites of the genus Dermatophagoides. ,A synthetic protein or polypeptide displaying the antigenicity of all or a portion of an allergen of house dust mites of the genus Devrmtophagoides. Methods of diagnosis and treating such allergies. > Diagnosis and treatment of neurological disease (GA Rosenberg et a/, US)
University of New Mexico, the Government of the United States of America, the Department of Health and Human Services N” WO 97109038, PCT. The invention provides a method for the diagnosis and treatment of neurological diseases or disorders characterized by disruption of the blood/brain barrier. The 92 kDa zymogen of gelatinase B and active gelatinase B are markers of neuropathologies associated with disruption of the blood/brain barrier.
> Utilisation d’un vecteur assurant I’expression ou I’augmentation transitoire de I’activit6 Bcl-2 (A Kahn et al, FR)
lnserm N” 2739561, FR. ... dans un ou plusieurs organes, pour la rkalisation d’un mtdicament destinC au traitement ou la prevention d’une defaillance aiguE d’un ou plusieurs organes impliquant un processus apoptotique, par inhibition totale ou partielle du signal apoptotique.